Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dynamics of the Immune Response in Acute Hepatitis B Infection.
Stelma F, Willemse SB, Erken R, de Niet A, Sinnige MJ, van Dort K, Zaaijer HL, van Leeuwen EMM, Kootstra NA, Reesink HW. Stelma F, et al. Among authors: de niet a. Open Forum Infect Dis. 2017 Dec 20;4(4):ofx231. doi: 10.1093/ofid/ofx231. eCollection 2017 Fall. Open Forum Infect Dis. 2017. PMID: 29302605 Free PMC article.
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Jansen L, de Niet A, Stelma F, van Iperen EP, van Dort KA, Plat-Sinnige MJ, Takkenberg RB, Chin DJ, Zwinderman AH, Lopatin U, Kootstra NA, Reesink HW. Jansen L, et al. Among authors: de niet a. J Hepatol. 2014 Oct;61(4):730-7. doi: 10.1016/j.jhep.2014.05.004. Epub 2014 May 10. J Hepatol. 2014. PMID: 24824278
Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial.
de Niet A, Jansen L, Stelma F, Willemse SB, Kuiken SD, Weijer S, van Nieuwkerk CMJ, Zaaijer HL, Molenkamp R, Takkenberg RB, Koot M, Verheij J, Beuers U, Reesink HW. de Niet A, et al. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584. doi: 10.1016/S2468-1253(17)30083-3. Epub 2017 May 15. Lancet Gastroenterol Hepatol. 2017. PMID: 28522204 Clinical Trial.
A Prospective Five-Year Follow-up After peg-Interferon Plus Nucleotide Analogue Treatment or no Treatment in HBeAg Negative Chronic Hepatitis B Patients.
Erken R, Loukachov VV, de Niet A, Jansen L, Stelma F, Helder JT, Peters MW, Zaaijer HL, Kootstra NA, Willemse SB, Reesink HW. Erken R, et al. Among authors: de niet a. J Clin Exp Hepatol. 2022 May-Jun;12(3):735-744. doi: 10.1016/j.jceh.2021.12.011. Epub 2022 Jan 4. J Clin Exp Hepatol. 2022. PMID: 35677522 Free PMC article.
Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW. Takkenberg RB, et al. Among authors: de niet a. Antivir Ther. 2013;18(7):895-904. doi: 10.3851/IMP2580. Antivir Ther. 2013. PMID: 23639931 Clinical Trial.
33 results